Anti-GRK6 antibody produced in rabbit

GRK6 (G protein-coupled receptor kinase 6) belongs to GRK family, and contains a central catalytic domain, which has N- and C-terminal on either sides. N-terminal is responsible for recognition of the receptor, and C-terminal is essential for plasma membrane binding of GRK6. This protein is composed of 576 amino acids, and has a molecular weight of 66kDa. This protein has a wide range of tissue expression.

G protein-coupled receptor kinase 6 recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

GRK6 (G protein-coupled receptor kinase 6) is involved in cell adhesion and locomotion, by phosphorylating and regulating chemokine receptor. It manipulates the organization of cytoskeleton and cell adhesion by controlling GRK-interacting protein (GIT1). It influences cAMP, epidermal growth factor receptor (EGFR) and calmodulin, thus, controlling the invasiveness and metastasis of tumor cells. It is up-regulated in hepatocellular carcinoma (HCC), and this is related to metastasis and prognosis of HCC. It has a major role in the phosphorylation of free fatty acid receptor 4 (FFA4), in a docosahexaenoic acid (DHA)-dependent manner. It regulates multiple leukocytes functions such as, activation of downstream effector signaling, receptor transport and localization at the cell membrane. This is achieved by controlling the involved CXCR2 protein, by forming a complex with AGS (activator of G-protein signaling)3-Gαi2. It is suppressed in medulloblastoma (MB), and this facilitates the migration of MB cells.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST73515

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.